Abstract
In recent years, prostate specific membrane antigen (PSMA) PET has attracted attention in the diagnosis of recurrence and metastasis of prostate cancer. PSMA is a membrane protein which shows increased expression in more than 90% of prostate cancer, and is known to exhibit high expression in many metastatic and recurrent lesions. In Osaka University Hospital, a clinical research using [18F]PSMA-1007 PET has been conducted since September 2019, and more than 150 scans has been performed so far in patients with prostate cancer with various stages.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
